FindTrial
Sign In

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-004086-32-FR
Enrollment
Unknown
Registered
2011-10-04
Start date
2012-04-10
Completion date
Unknown
Last updated
2015-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus MedDRA version: 17.0 Level: LLT Classification code 10063624 Term: Type II diabetes mellitus inadequate control System Organ Class: 100000004861

Interventions

Product Name: imeglimin Product Code: PXL008 Pharmaceutical Form: Tablet INN or Proposed INN: imeglimin CAS Number: 775351-61-6 Current Sponsor code: PXL008 Concentration unit: mg milligram(s) Concent

Sponsors

POXEL
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Contacts

Public ContactClinical Development

POXEL

isabelle.tronel@poxelpharma.com33437372010

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026